Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A289VV1
Wed, 30.03.2022
HAEMATO AG
______________________________________________________________________________
HAEMATO AG publishes preliminary figures for the 2021 financial year:
Renewed increase in sales and strong rise in earnings after disproportionate growth of the new Lifestyle and Aesthetics business unit
- HAEMATO remains on course for growth: according to preliminar [ … ]
Mon, 28.03.2022
HAEMATO AG
______________________________________________________________________________
Expansion of the Executive Board of HAEMATO AG: Strengthening operational excellence
Schönefeld, 28.03.2022 - In its meeting today, the Supervisory Board of HAEMATO AG appointed Mr. Attila Strauss to the Executive Board of HAEMATO AG with effect from 01.04.2022.
Mr. A [ … ]
Thu, 24.02.2022
Haemato AG
First Berlin Equity Research hat ein Research Update zu Haemato AG (ISIN:
DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von EUR 50,00.
Zusammenfassung:
Haemato hat ihr Medizinprodukte-Portfolio um ein zweites
Point-of-Care-Testgerät erweitert. Im Januar begann da [ … ]
Tue, 15.02.2022
HAEMATO AG
DGAP-Media / 15.02.2022 / 14:45
Schönefeld, 15 February 2022 - HAEMATO PHARM GmbH ("HAEMATO"), a 100% subsidiary of HAEMATO AG (ISIN: DE000289VV1), is expanding its medical device portfolio in the fight against Corona virus. In addition to the already introduced Point-of-Care (PoC) PCR device, HAEMATO is now also marketing the Mini Dock, an [ … ]
Fri, 28.01.2022
HAEMATO AG
PCR PoC-Device added to the product portfolio; revenue and earnings
forecasts unchanged, upside potential anticipated from new products, price
target and BUY rating confirmed
In our last management interview (http://www.more-ir.de/d/23165.pdf) on the
current developments of HAEMATO AG, the CEO Patrick Brenske had announced
the addition of a mobi [ … ]
Tue, 18.01.2022
Haemato AG
First Berlin Equity Research hat ein Research Update zu Haemato AG (ISIN:
DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von EUR 50,00.
Zusammenfassung:
Während Omikron Europa stürmt, bemühen sich die Regierungen, die neue
Variante zu stoppen, und die st [ … ]
Fri, 14.01.2022
HAEMATO AG
DGAP-Media / 14.01.2022 / 14:45
HAEMATO distributes PCR point-of-care devices for effective containment of corona pandemic
Schönefeld, 13th January 2022 - With the current omicron wave, laboratories in Germany are facing a sharp increase in PCR testing. The evaluation capacities are pushing increasingly towards their limits, especially with [ … ]
Fri, 10.12.2021
HAEMATO AG
In operational terms, HAEMATO AG is heading for a record year following the
acquisition of M1 Aesthetics GmbH. In addition, the expansion of their
private label business is increasingly coming into focus. In this regard,
the company plans to expand its portfolio with a botulinum toxin product
under its own brand. GBC analyst Cosmin Filker spoke wi [ … ]
Thu, 09.12.2021
Haemato AG
First Berlin Equity Research hat ein Research Update zu Haemato AG (ISIN:
DE000A289VV1) veröffentlicht. Analyst Ellis Acklin bestätigt seine
BUY-Empfehlung und bestätigt sein Kursziel von EUR 50,00.
Zusammenfassung:
Haemato hat Q3-Kennzahlen gemeldet, die eine anhaltend gute
Geschäftsdynamik zeigten, angeführt von einem [ … ]
Thu, 18.11.2021
HAEMATO AG
______________________________________________________________________________
HAEMATO AG reports figures for the 3rd quarter of 2021: Further increase in revenue and earnings as well as confirmation of revenue and earnings expectations for 2021
- HAEMATO continues to grow: consolidated revenue in the third quarter of 2021 increased by 9% year-ov [ … ]